Sulfotransferases (STs) are ubiquitous enzymes that participate in a vast number of biological processes involving sulfuryl group (SO3) transfer. 3'-phosphoadenosine 5'-phosphosulfate (PAPS) is the universal ST cofactor, serving as the "active sulfate" source in cells. Herein, we report the synthesis of three fluorinated PAPS analogues that bear fluorine or trifluoromethyl substituents at the C2 or C8 positions of adenine and their evaluation as substitute cofactors that enable ST activity to be quantified and real-time-monitored by fluorine-19 nuclear magnetic resonance (19F NMR) spectroscopy. Using plant AtSOT18 and human SULT1A3 as two model enzymes, we reveal that the fluorinated PAPS analogues show complementary properties with regard to recognition by enzymes and the working 19F NMR pH range and are attractive versatile tools for studying STs. Finally, we developed an 19F NMR assay for screening potential inhibitors against SULT1A3, thereby highlighting the possible use of fluorinated PAPS analogues for the discovery of drugs for ST-related diseases.
Sulfotransferases (STs) are ubiquitous enzymes that participate in a vast number of biological processes involving sulfuryl group (SO3) transfer. 3'-phosphoadenosine 5'-phosphosulfate (PAPS) is the universal ST cofactor, serving as the "active sulfate" source in cells. Herein, we report the synthesis of three fluorinated PAPS analogues that bear fluorine or trifluoromethyl substituents at the C2 or C8 positions of adenine and their evaluation as substitute cofactors that enable ST activity to be quantified and real-time-monitored by fluorine-19 nuclear magnetic resonance (19F NMR) spectroscopy. Using plant AtSOT18 and human SULT1A3 as two model enzymes, we reveal that the fluorinated PAPS analogues show complementary properties with regard to recognition by enzymes and the working 19F NMR pH range and are attractive versatile tools for studying STs. Finally, we developed an 19F NMR assay for screening potential inhibitors against SULT1A3, thereby highlighting the possible use of fluorinated PAPS analogues for the discovery of drugs for ST-related diseases.
Sulfotransferases (STs)
are enzymes that catalyze the transfer
of sulfuryl (SO3) groups to various nucleophilic acceptors.[1] Sulfotransferase-catalyzed reactions occur in
all living domains, including bacteria, plants, and animals, and are
involved in a variety of processes, such as enzyme regulation, detoxification,
regulating hormonal balance, molecular recognition, and cellular signaling.
Several human STs have been identified as biomarkers linked to cancer,[2] neurodegenerative diseases,[3,4] immune
response effectiveness,[5] and multiple other
disorders.[6] The vast majority of STs, including
mammalian sulfotransferases (SULTs) and plant sulfotransferases (SOTs),
use 3′-phosphoadenosine 5′-phosphosulfate (PAPS) as
a universal cofactor, that is, a sulfate group donor. STs transfer
the sulfuryl group from PAPS to acceptor molecules bearing O- or N-nucleophilic functional groups and release PAP as the
byproduct (Figure A). ST substrate specificity varies from small molecules to complex
macromolecules, including proteins and proteoglycans.
Figure 1
General reaction catalyzed
by a PAPS-dependent sulfotransferase
(ST) (A) and fluorinated PAPS analogues synthesized and evaluated
in this study (B).
General reaction catalyzed
by a PAPS-dependent sulfotransferase
(ST) (A) and fluorinated PAPS analogues synthesized and evaluated
in this study (B).The biological importance
of sulfotransferase-catalyzed reactions
necessitates the development of robust assays for monitoring and screening
sulfotransferase activity. Despite a number of methods developed with
this goal in mind,[7] the majority relies
on the detection and quantification of enzyme-specific substrates,[8] which significantly narrows their application
scope.[9] To the best of our knowledge, the
only universal method for assaying STs involves the use of PAPS labeled
with radioactive 35S [(35S)PAPS].[10] Although the method is highly sensitive, the
use of radioactive isotopes is limiting because it necessitates separating
radioactive substrates and products and cannot be used to continuously
monitor ST activity.Fluorinated analogues of substrates for
nucleotide-dependent enzymes
have recently emerged as invaluable tools for enzymatic activity monitoring
and inhibitor discovery by fluorine-19 nuclear magnetic resonance
(19F NMR).[11−13] For instance, 2-fluoro-ATP was shown to acts as a
kinase substrate suitable for activity-based screening,[12] whereas trifluoromethylated purine nucleotides
were used to monitor activity of different phosphohydrolases.[13] In this study, we aimed to develop a generally
applicable 19F NMR-based assay employing fluorinated PAPS
analogues suitable for sulfotransferase activity monitoring and screening
both at a single time point and in real time. We envisaged that a
fluorinated PAPS analogue that serves as an ST cosubstrate and is
characterized by a 19F chemical shift different from that
of the corresponding PAP analogue can be used to monitor reaction
progress by 19F NMR spectroscopy. To explore this idea,
we synthesized three PAPS analogues bearing fluorine or trifluoromethyl
substituents at the C2- or C8-positions of the adenine moiety (Figure B). We characterized
the 19F NMR-related properties of the compounds and evaluated
them as cosubstrates for two model sulfotransferases, namely the plant
sulfotransferase AtSOT18 (involved in plant signaling) and mammalian
sulfotransferase SULT1A3 (involved in the metabolism of biogenic amines).[14,15]We found that the compounds have promising substrate- and 19F-NMR-related properties and thereby are potentially versatile
molecular tools for STs. One of the compounds was successfully used
to screen a library of 59 ligands against SULT1A3.
Results and Discussion
To investigate the development of a 19F-labeled cofactor
for sulfotransferases, we designed three fluorinated PAPS analogues
as potential sulfotransferase substrates (Figure B; compounds 1–3). Analogue 1 has a single fluorine substituent at the C2-position of
adenine, whereas 2 and 3 each contains a
trifluoromethyl group at either the C2- or C8-position. We aimed to
compare the properties of the monofluoro- and trifluoromethyl-substituted
compounds, as the presence of three equivalent fluorine atoms should
increase the sensitivity and quality of the 19F NMR signal;
however, it may affect the shape and conformation of the PAPS molecule
to some extent, possibly resulting in a broader range of ST enzymes
rejecting the modified compound as a cofactor. We also attempted to
synthesize 8-fluoro-substituted PAPS but found that 8-fluoroadenosine
is highly susceptible to depurination, which made the synthesis impossible
to complete. Compounds 1–3 were synthesized in
several chemical steps including a final enzymatic cleavage step (Scheme ). Unprotected fluorinated
nucleosides 4a–c used as starting materials were
either obtained from commercial sources (4a) or synthesized
by recently reported procedures (4b, 4c).[13,16]
Scheme 1
Synthesis of Fluorinated PAPS Analogues 1–3
Reaction conditions: (a) POCl3, PO(OCH3)3 at 0 or −5 °C
and 2,6-lutidine (for 4b, 4c). (b) 1. POCl3; 2. precipitation with Et2O. (c) Imidazole, PO(OCH3)3. (d) H2O. (e) Bis(tributylammonium)
sulfate, MgCl2, DMF. (f) RNAse T2 (50 mM ammonium acetate
buffer, pH 7.3, 37 °C, 300 rpm), 24 h.
Synthesis of Fluorinated PAPS Analogues 1–3
Reaction conditions: (a) POCl3, PO(OCH3)3 at 0 or −5 °C
and 2,6-lutidine (for 4b, 4c). (b) 1. POCl3; 2. precipitation with Et2O. (c) Imidazole, PO(OCH3)3. (d) H2O. (e) Bis(tributylammonium)
sulfate, MgCl2, DMF. (f) RNAse T2 (50 mM ammonium acetate
buffer, pH 7.3, 37 °C, 300 rpm), 24 h.The 5′-phosphorimidazolides of appropriate 2′,3′-cyclophosphonucleosides
were crucial synthetic intermediates and were prepared using a one-pot
three-step procedure (5a–c; Scheme ). To that end, a suspension of 4a–c (1 equiv) in trimethyl phosphate was treated with anhydrous POCl3 (3 equiv) at −5 or 0 °C. The addition of 3 equiv
of 2,6-lutidine was required for 4b and 4c to avoid depurination. The reaction was allowed to proceed until
reversed-phase high-performance liquid chromatography (RP-HPLC) revealed
complete conversion of the substrate to the corresponding 5′-phosphorylated
product (approximately 3–4 h). A second portion of POCl3 (6 equiv) was then added, and the reaction was allowed to
proceed (usually overnight) to enable phosphorylation at the 2′/3′-position
of the nucleoside (see the Supporting Information for details). The diphosphorylated intermediate was precipitated
with cold diethyl ether and centrifuged, after which it was re-dissolved
in trimethyl phosphate (to a concentration of ∼100 mM), excess
imidazole was added, incubated for 1 h at RT, and then hydrolyzed.
The resulting products 5a–c were purified by ion-exchange
chromatography and stored as DMF solutions to avoid decomposition,
which occurred when we attempted to isolate them in the solid form.
Compounds 5a–c were then coupled with tributylammonium
sulfate (4 equiv) in DMF in the presence of excess MgCl2 (8 equiv).[17] These reactions were complete
within 18 h with conversions of 27–52%, as determined by RP-HPLC.
The product was purified by ion-exchange chromatography (DEAE Sephadex)
followed by semi-preparative RP-HPLC. Finally, the 2′,3′-cyclophosphate
was enzymatically cleaved to the 3′-phosphate in high yield
(∼90%) using RNAse T2.[18]We
next examined how well PAPS analogues 1–3 were
accepted as cofactors in sulfotransferase-catalyzed biochemical
reactions. To this end, each compound 1–3 was
incubated with model sulfotransferases and their specific substrates
under conditions previously found to be optimal for these enzymes,
with reaction progress monitored independently by 19F NMR
spectroscopy (Figure A–H) and RP-HPLC (Figures I,J; S1, S2). As model enzymes,
we chose two sulfotransferases of different origin and substrate specificity:
plant AtSOT18[14,19] and human SULT1A3.[20] AtSOT18 participates in the biosynthesis of
glucosinolates that are precursors of mustard oils and are responsible
for the properties of many pungent plants,[21] while SULT1A3 is a human enzyme involved in the metabolism of endogenous
catecholamines (e.g., dopamine and epinephrine), serotonin, and structurally
related xenobiotics.[22] SULT1A3 has been
shown to protect neurons from dopamine cytotoxicity and has been linked
to neurodegenerative diseases and liver cancer.[4,23]
Figure 2
Evaluating
fluorinated PAPS analogues as universal sulfotransferase
substrates by 19F NMR spectroscopy. (A) 2-F-PAPS with AtSOT18;
(B) 2-F-PAPS with SULT1A3; (C) 2-F-PAPS with AtSOT18 and a 200 μM
inhibitor (PAP); (D) 2-CF3-PAPS with ATSOT18; (E) 2-CF3-PAPS with SULT1A3; (F) 8-CF3-PAPS with AtSOT18;
(G) 8-CF3-PAPS with SULT1A3; (H) 8-CF3-PAPS
with SULT1A3 and a 200 μM inhibitor (PAP); (I) RP-HPLC trace
of the AtSOT18-catalyzed reaction in the presence of 2-CF3-PAPS after 60 min; and (J) RP-HPLC trace of the SULT1A3-catalyzed
reaction in the presence of 2-CF3-PAPS after 60 min. The
inset shows reactions catalyzed by both enzymes. Reaction conditions:
AtSOT18 −200 μM PAPS analogue, 200 μM desulfosinigrin,
100 nM enzyme in 83 mM Tris, pH 9.0, containing 9.2 mM MgCl2, and 10% D2O at 37 °C; SULT1A3 −200 μM
PAPS analogue, 200 μM dopamine, 100 nM enzyme in 6.7 mM K2HPO4, pH 7.4, containing 10% D2O at
37 °C.
Evaluating
fluorinated PAPS analogues as universal sulfotransferase
substrates by 19F NMR spectroscopy. (A) 2-F-PAPS with AtSOT18;
(B) 2-F-PAPS with SULT1A3; (C) 2-F-PAPS with AtSOT18 and a 200 μM
inhibitor (PAP); (D) 2-CF3-PAPS with ATSOT18; (E) 2-CF3-PAPS with SULT1A3; (F) 8-CF3-PAPS with AtSOT18;
(G) 8-CF3-PAPS with SULT1A3; (H) 8-CF3-PAPS
with SULT1A3 and a 200 μM inhibitor (PAP); (I) RP-HPLC trace
of the AtSOT18-catalyzed reaction in the presence of 2-CF3-PAPS after 60 min; and (J) RP-HPLC trace of the SULT1A3-catalyzed
reaction in the presence of 2-CF3-PAPS after 60 min. The
inset shows reactions catalyzed by both enzymes. Reaction conditions:
AtSOT18 −200 μM PAPS analogue, 200 μM desulfosinigrin,
100 nM enzyme in 83 mM Tris, pH 9.0, containing 9.2 mM MgCl2, and 10% D2O at 37 °C; SULT1A3 −200 μM
PAPS analogue, 200 μM dopamine, 100 nM enzyme in 6.7 mM K2HPO4, pH 7.4, containing 10% D2O at
37 °C.A reaction mixture containing
2-F-PAPS (1), either
AtSOT18 or SULT1A3, and the corresponding ST-specific substrate (desulfosinigrin
or dopamine, respectively) was monitored by 19F NMR spectroscopy,
which revealed that 1 is accepted by each enzyme as a
cofactor. Each 19F NMR spectrum consisted of a single signal
at approximately −52.5 ppm that corresponds to 2-F-PAPS prior
to the addition of the enzyme (Figure ; the chemical shifts are slightly different for the
two enzymes due to different buffer compositions). The signal corresponding
to 2-F-PAPS gradually decreased in the presence of the enzyme, while
a new signal that was downfield shifted by 0.02 ppm emerged (Figure A,B). This new signal
increased slowly in the presence of PAP, the natural sulfotransferase
inhibitor (Figure C), and was not observed in the absence of the enzyme (Figure S3), suggesting that it corresponds to
2-F-PAP, the enzymatic reaction byproduct. RP-HPLC supported by electrospray
ionization mass spectrometry confirmed that 2-F-PAPS had been converted
into 2-F-PAP and that sulfotransferase-specific products had formed:
sinigrin for AtSOT18 (Figure S1) or two
isomers of dopamine sulfate for SULT1A3 (Figure S2). In addition, these experiments also revealed that 2-F-PAPS
has substrate properties comparable to those of unmodified PAPS.In contrast, the 19F NMR spectrum of 2-CF3-PAPS
(2) incubated with either AtSOT18 or SULT1A3 did
not change over time (Figure D,E), which may indicate that either 2-CF3-PAPS
is not accepted as a cosubstrate by the enzyme or that 2-CF3-PAPS and 2-CF3-PAP signals overlap under the experimental
conditions. RP-HPLC of analogously prepared samples incubated for
1 h with each enzyme revealed the formation of the corresponding sulfated
product, albeit with lower efficiency than that of PAPS (Figures I,J; S1D, S2D). This clearly indicates that while
compound 2 is a substrate for AtSOT18 and SULT1A3, the
reaction progress cannot be continuously monitored by 19F NMR spectroscopy under the applied conditions.Interestingly,
8-CF3-PAPS (3) was recognized
differently by the above-mentioned two enzymes. The formation of the
8-CF3-PAP analogue was not observed by 19F NMR
spectroscopy in the presence of AtSOT18, whereas two signals with
intensities that changed over time were clearly visible in the presence
of SULT1A3 (Figure F–H). RP-HPLC of the reaction mixture after incubating with
AtSOT18 or SULT1A3 for 1 h confirmed that 8-CF3-PAPS is
a good substrate for SULT1A3 (comparable to PAPS) under the studied
conditions but not for AtSOT18 (Figures S1, S2).Overall, these studies revealed that all three compounds
are potential
molecular tools for sulfotransferase research; however, each is associated
with some limitations. 2-F-PAPS serves as a substrate for each enzyme,
with the signal of the fluorinated substrate well resolved from that
of the product (2-F-PAP) in each case. However, because only a single
fluorine atom is used as the 19F label, the spectra acquired
using 2-F-PAPS are of lower quality (signal-to-noise ratio) than those
obtained using 2-CF3-PAPS or 8-CF3-PAPS at the
same concentration. 2-CF3-PAPS is a substrate for both
enzymes and produces spectra of good quality; consequently, it is
a good potential universal sulfotransferase co-factor candidate. Unfortunately,
the 19F signals of 2-CF3-PAPS and 2-CF3-PAP overlap under the studied conditions; hence, monitoring reaction
progress by 19F NMR spectroscopy is impossible. Finally,
8-CF3-PAPS provided spectra of good quality with a signal
that was well-resolved from that of 8-CF3-PAP, but the
compound was only accepted as a substrate by SULT1A3 and not AtSOT18;
hence, it may be of limited applicability compared to other two compounds.The 19F signal-separation problem observed for 2-CF3-PAPS and 2-CF3-PAP encouraged us to systematically
search for conditions under which the resonances corresponding to
the PAPS analogues and their corresponding PAP counterparts are well
resolved. We hypothesized that the chemical shifts of the signals
corresponding to the PAPS and PAP analogues may be affected by their
protonation state. Because PAPS contains a single ionizable group
at pH ≈ 7 (3′-phosphate) and PAP contains two such groups
(3′-phosphate and 5′-phosphate; Figure S4), different pH-dependent effects may be observed
for the two compounds. Consequently, we investigated chemical shifts
as functions of solution pH (Figure ). To that end, aqueous solutions of PAPS analogues 1–3 were subjected to acidic hydrolysis to obtain non-equimolar
mixtures of PAPS and PAP analogues. The pH of each mixture was then
adjusted to 4 and step-wise titrated with aqueous NaOH to pH 9 (in
∼0.5 pH unit steps). The 19F NMR spectrum of the
mixture was recorded at each step, and the δF values
of the PAPS and PAP analogues were plotted as functions of pH. Interestingly,
each compound exhibited unique pH-dependent properties, with the 2-F-PAPS/2-F-PAP
pair being most sensitive to pH change (Figure ).
Figure 3
pH-dependent changes in δF for
PAPS analogues 1–3 and the corresponding PAP analogues.
(A) Representative 19F NMR [471 MHz, 200 μM total
nucleotides in 6.7 mM
K2HPO4 with 10% of D2O (v/v), 37
°C] spectra from titration experiments of PAPS/PAP analogue mixtures.
(B) Titration curves obtained from duplicate experiments. Data points
are means ± standard deviations. Solid lines are theoretical
curves fitted to the data points (see the Experimental Section).
pH-dependent changes in δF for
PAPS analogues 1–3 and the corresponding PAP analogues.
(A) Representative 19F NMR [471 MHz, 200 μM total
nucleotides in 6.7 mM
K2HPO4 with 10% of D2O (v/v), 37
°C] spectra from titration experiments of PAPS/PAP analogue mixtures.
(B) Titration curves obtained from duplicate experiments. Data points
are means ± standard deviations. Solid lines are theoretical
curves fitted to the data points (see the Experimental Section).The signals for the 2-F-PAPS/2-F-PAP pair were
well resolved at
pH values in the 4.0–6.0 range (ΔδF ppm:
0.05–0.1) and between 8.0 and 9.0 (ΔδF 0.05 ppm), whereas separation was less efficient at pH 6.5–7.5,
with almost complete overlap observed at pH 7.0. The 2-CF3-PAPS/2-CF3-PAP pair was the least sensitive to pH change
and also provided the poorest signal separation. Nonetheless, sufficient
signal separation was achieved at pH 4.0–5.5 (ΔδF 0.01–0.02 ppm), with slightly poorer separation observed
at pH 8.5–9.0 (ΔδF ppm: 0.01). In contrast,
the signals associated with the 8-CF3-PAPS/8-CF3-PAP pair were resolved similarly well over a wide pH range (6.0–9.0;
ΔδF ppm: 0.01–0.03). Considering that
most sulfotransferases exhibit optimum activity under neutral or slightly
alkaline conditions and that the phosphosulfate bonds in PAPS are
susceptible to acidic hydrolysis, we recommend optimum pH ranges for
these analogues (Table ).
Table 1
Optimized Conditions for 19F NMR-Monitored
Sulfotransferase Experimentsa
AtSOT18
compound
recommended assay type and pH rangeb
assay type
buffer
δF PAPS analogue (ppm)
δF PAP analogue (ppm)
1 (2-F-PAPS)
real-time, end-point(discontinuous),pH 7.5–9.0
real-time
83 mM tris pH 9.0, 9.2 mM MgCl2 with 10% D2O
–52.47
–52.45
2 (2-CF3-PAPS)
end-point, 8.5–9.0
end-point
reaction: 83 mM tris, pH 8.5, 10% D2O readout: 1:1 mixture (v/v) of reaction buffer and acetonitrile
–68.76
–68.74
3 (8-CF3-PAPS)
real-time, end-point, pH 6.5–9.0
real-time
not activec
–61.01
not active
Representative 19F NMR
spectra acquired under these conditions are shown in Figures and S5.
Optimal pH for 19F NMR
monitoring/readout.
Compound 3 is not a
substrate for AtSOT18.
Representative 19F NMR
spectra acquired under these conditions are shown in Figures and S5.
Figure 4
Endpoint 19F NMR assay overview. Spectra of ST-catalyzed
reactions acquired using 2-CF3-PAPS under optimized conditions
(showcased in Table ) at the 40 min timepoint.
Optimal pH for 19F NMR
monitoring/readout.Compound 3 is not a
substrate for AtSOT18.The
pH studies explain why good signal separation was not observed
for enzymatic reactions conducted in the presence of 2-CF3-PAPS at pH 7.4 (reaction with SULT1A3) but do not account for the
lack of separation observed at pH 9.0 (for AtSOT18). We speculate
that the presence of protein and buffer components additionally contributes
to 19F NMR signal broadening that hampers signal separation.
Therefore, we investigated the development of a discontinuous (endpoint)
assay, in which different conditions were used for the enzymatic reaction
and 19F NMR measurements. After optimization studies, we
found that adding 50% acetonitrile to the reaction mixture causes
protein denaturation and in consequence improves the signal shape.
This finding enabled the development of discontinuous assay conditions
for 2-CF3-PAPS and both AtSOT18 and SULT1A3 enzymes, thereby
establishing the final set of conditions recommended for all compounds
and each enzyme (Figures , S5; Table ). Therefore, despite
2-CF3-PAPS having limited applicability for real-time ST-activity
monitoring, it may still be useful for various experiments, such as
end-point analyses and activity-based screening assays.Endpoint 19F NMR assay overview. Spectra of ST-catalyzed
reactions acquired using 2-CF3-PAPS under optimized conditions
(showcased in Table ) at the 40 min timepoint.Finally, we performed a proof-of-concept SULT1A3 activity-screening
experiment to demonstrate the practical utility of fluorinated PAPS
analogues. To that end, we selected a subset of compounds from the
LOPAC1280 library and added them to SULT1A3-catalyzed reactions in
the 96-well format in the presence of 8-CF3-PAPS. Control
reactions included samples without an inhibitor, without a protein,
and with the addition of a natural ST inhibitor (PAP). All reactions
were terminated at a single time point (40 min), transferred to NMR
tubes, and subjected to 19F NMR spectroscopy to assess
inhibition percentage (Figure ; Table S1). Three hits were identified
among the 59 screened compounds: 6-hydroxydopamine, which had been
previously identified as a competitive inhibitor of SULT1A3/4,[24] and 8-(p-sulfophenyl)teophiline
and CGS-15943, which have not been previously studied in the context
of STs but had been identified as adenosine receptor antagonists.[25]
Figure 5
19F NMR-based screening of a small library
of pharmaceutically
active compounds against SULT1A3. Samples A1, G8, and H8 (black frames):
positive controls (reactions without an inhibitor): samples B1 and
F8 (blue frame): negative controls (reactions without an enzyme).
Sample E8 (orange frame): inhibition control (reaction in the presence
of PAP). Samples D5, G1, and H2: hits confirmed by duplicate screening
(Table S1).
19F NMR-based screening of a small library
of pharmaceutically
active compounds against SULT1A3. Samples A1, G8, and H8 (black frames):
positive controls (reactions without an inhibitor): samples B1 and
F8 (blue frame): negative controls (reactions without an enzyme).
Sample E8 (orange frame): inhibition control (reaction in the presence
of PAP). Samples D5, G1, and H2: hits confirmed by duplicate screening
(Table S1).
Conclusions
2-F-PAPS (1), 2-CF3-PAPS (2), and 8-CF3-PAPS (3) were investigated as
PAPS substitutes in ST-catalyzed reactions. The compounds were synthesized
from unprotected nucleosides in a straightforward manner that can
provide access to sufficient quantities for large-scale applications.
Substrate properties of the compounds were evaluated in the context
of two unrelated enzymes (AtSOT18 and SULT1A3), which revealed that
all three compounds are promising molecular tools for sulfotransferases.
2-F-PAPS (1) and 2-CF3-PAPS (2) were accepted as co-factors by both studied enzymes, which is a
good premise for potential broad applicability, and enabled reaction
progress to be monitored by 19F NMR spectroscopy either
in a real-time or in discontinuous format. 8-CF3-PAPS (3) was well accepted as a substrate by SULT1A3 but not AtSOT18,
which suggests that it may be compatible with a more limited range
of enzymes.Because the vast majority of sulfotransferases are
PAPS-dependent
enzymes, the 19F NMR assays reported herein are potentially
generally applicable, being possibly limited only by the PAPS recognition
requirements of the particular enzymes. Although screening against
a broader panel of sulfotransferases and the determination of kinetic
parameters should be performed in the future to explore the full potential
and limitations of those novel tools, previous structural studies
indicate that the PAPS-binding site is conserved between different
STs,[1,26] strongly suggesting broader applicability
of our findings. Future studies should take into account that the KM values of unmodified PAPS for different sulfotransferases
vary from medium nanomolar to medium micromolar values, and if the KM of the PAPS analogue is significantly lower
than its concentration used in the assay, this will bias the sensitivity
of the assay toward uncompetitive and non-competitive inhibitors.[27]Overall, our study revealed that fluorinated
PAPS analogues are
promising molecular tools for studying sulfotransferase activity by 19F NMR spectroscopy. To the best of our knowledge, this study
demonstrated the first proof of concept of a universal (i.e., PAPS-based)
ST assay that does not rely on radioactivity. Because contemporary 19F NMR-based assays are highly versatile, the developed approach
may benefit various ST-related research areas, including ST-specific
substrate specificity profiling, comparing ST isoform activities,
activity-based inhibitor screening against therapeutically relevant
sulfotransferases, or assaying the ST activities in complex biological
mixtures (e.g., cell lysates or tissue homogenates).
Methods
General Information
19F NMR spectra were
recorded with a BRUKER AVANCE III HD spectrometer equipped with PA
BBO 500S1 BBF-H-D-05 Z SP probe at 471 MHz (probe sensitivity: 550
S/N ratio for 0.05% trifluorotoluene in chloroform-D). 19F NMR chemical shifts were calibrated to 0.1 M NaF in D2O (δF = −121.5 ppm) as an external standard.
All NMR spectra were analyzed by MestReNova 12.0.1 19F
NMR parameters used for general compound characterization: 19F excitation pulse, 15.1 μs; acquisition time, 0.57 s; relaxation
delay, 1.0 s; number of scans, 128; spectral width, 240 ppm; and spectral
resolution, 0.83 Hz.
19F NMR Parameters Used for Enzymatic
Experiments
19F excitation pulse, 15.1 μs;
acquisition time,
0.57 s; relaxation delay, 1.0 s; number of scans, 128; spectral width,
15 ppm; transmitter frequency offset, −52.5 ppm; and spectral
resolution, 1.72 Hz.
Real-Time Experiments (Compounds 1 and 3)
Before each experiment, the sample
without the enzyme
was incubated inside a magnet at 37 °C for 5 min and then locked,
tuned, and shimmed, and initial 128 scans were recorded. After addition
of protein, the spectra were recorded with fixed delays (300 s), and
the number of experiments was set to 10. Conditions for the AtSOT18
protein were as follows: for 1 and 3: 200
μM PAPS analogue, 200 μM desulfosinigrin, 100 nM enzyme,
83 mM Tris buffer, pH 9.0, 9.2 mM MgCl2, and 10% D2O, 37 °C; conditions for the SULT1A3 protein were as
follows: 200 μM 2-F-PAPS (1), 200 μM dopamine,
100 nM enzyme, 6.7 mM K2HPO4, pH 6.5, and 10%
D2O at 37 °C; or 200 μM 8-CF3-PAPS
(3), 200 μM dopamine, 100 nM enzyme, 6.7 mM K2HPO4, pH 7.4, and 10% D2O at 37 °C.
End-Point Assay (Compound 2)
Conditions
for AtSOT18:[14] 200 μM 2-CF3-PAPS (2), 200 μM desulfosinigrin, 100 nM enzyme,
83 mM Tris buffer, pH 9.0, 9.2 mM MgCl2, and 10% D2O (275 μL in total). The reaction mixture was placed
in a thermoblock at 37 °C, 300 rpm for 40 min. After this time,
the reaction was terminated by the addition of acetonitrile (1:1;
v/v), centrifuged, transferred to an NMR tube, and analyzed by 19F NMR; conditions for SULT1A3:[15] 200 μM 2-CF3-PAPS (2), 200 μM
dopamine, 100 nM enzyme, 6.7 mM K2HPO4, pH 7.4,
and 10% D2O (200 μL in total). The reaction mixture
was placed at 37 °C, 300 rpm for 40 min. After this time, the
reaction was stopped by addition of acetonitrile (200 μL), adjusted
to pH 8.5 by the addition of the mixture of 30 mM K2HPO4 buffer, pH 9.5, and 10% D2O (200 μL in total),
centrifuged, transferred to an NMR tube, and analyzed by 19F NMR.
Stability Experiments
Before each experiment, the sample
without the enzyme was incubated inside a magnet at 37 °C for
5 min and then locked, tuned, and shimmed, and initial 128 scans were
recorded. Each stability experiment was recorded with a fixed delay
of 1800 s, and the number of experiments was set to 35.
pH-Dependent
Titrations
The mixtures of PAPS (1–3) and corresponding PAP analogues were
prepared as follows: 10 mM solution of each PAPS analogue in H2O was adjusted to pH 3. The samples were incubated for ∼20
h at 37 °C, and progress of PAPS to PAP conversion was monitored
by RP HPLC. The hydrolysis was continued until RP HPLC revealed formation
of a non-equimolar mixture of PAPS/PAP with at least a 20% content
of PAP. The samples for titration experiments were prepared as follows:
the PAP and PAPS mixture generated by acidic hydrolysis was diluted
to 200 μM (total concentration of nucleotides) in 6.7 mM K2HPO4 buffer containing 10% D2O, and
pH of the resulting solutions was adjusted to 4.0. The solutions were
centrifuged and transferred to NMR tubes, incubated inside a magnet
at 37 °C for 5 min and then locked, tuned, and shimmed, and initial
128 scans were recorded. The samples were titrated by the addition
of aq. NaOH (0.1 M), and pH was determined directly in the NMR tube
(Extended Length pH Electrode with Micro Bulb, Hanna Instruments). 19F NMR spectra were recorded between pH 4.0–9.0 at
approx. 0.5 unit steps. Each titration was performed in duplicate.
Screening for SULT1A3
Enzymatic reactions for the screening
of the LOPAC1280 library were performed in 96-well deep-well plates
(BrandTech 701352 Deep-Well Plate, 96-well, PS, 1.1 mL, Standard,
U-Bottom). Each well contained 200 μM 8-CF3-PAPS
(3), 200 μM dopamine, the 35 μM tested inhibitor
candidate (0.96 μL of the 10 mM stock solution), and 100 nM
protein in 6.7 mM K2HPO4, pH 7.4, with addition
of 10% D2O (275 μL in total). The control reaction
without the inhibitor (performed in triplicate) included 35 μM
(0.96 μL) DMSO instead of the inhibitor. The control reaction
without protein (performed in triplicate) included water instead of
the enzyme. The reactions were carried out at 37 °C for 40 min
with mixing (300 rpm). After this time, each reaction was quenched
by adding acetonitrile (275 μL) followed by 10 μL of buffered
EDTA solution (20 mg mL–1 EDTA, 10 mg/mL–1+ NaHCO3) and was centrifuged, transferred to NMR tubes,
and analyzed by 19F NMR.
Authors: R Dajani; S Sharp; S Graham; S S Bethell; R M Cooke; D J Jamieson; M W Coughtrie Journal: Protein Expr Purif Date: 1999-06 Impact factor: 1.650
Authors: Dominik D Kaltenbach; Dinesh Jaishankar; Meng Hao; Jacob C Beer; Michael V Volin; Umesh R Desai; Vaibhav Tiwari Journal: Front Pharmacol Date: 2018-11-22 Impact factor: 5.810